Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like AutomationDirect announces VFD-SC series of VFD cables January 15, 2020 HMS Networks announces integration with Canary Labs' Canary Enterprise Historian November 8, 2019 IBC cases: Govt in talks with RBI to relax provisioning norms October 12, 2017